These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2317160)

  • 61. Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property.
    Jandu N; Richardson M; Singh G; Hirte H; Hatton MW
    Int J Gynecol Cancer; 2006; 16(4):1536-44. PubMed ID: 16884362
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Characterization of fibrin(ogen) fragments in gingival crevicular fluid.
    Talonpoika J
    Scand J Dent Res; 1991 Feb; 99(1):40-3. PubMed ID: 2047751
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Biological behavior of higher molecular weight products of fibrinolysis.
    Chang ML; Bang NU
    J Lab Clin Med; 1977 Jul; 90(1):216-26. PubMed ID: 874368
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The fibrin intermediate, its place in the fibrinogen-fibrin transformation.
    Shainoff JR; Smejkal GB; Dibello PM; Chase B; Mitkevich OV; Lill H
    Ann N Y Acad Sci; 2001; 936():147-66. PubMed ID: 11460472
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The release of B beta 1-42 from fibrinogen and fibrin by plasmin.
    Hurlet-Jensen A; Koehn JA; Nossel HL
    Thromb Res; 1983 Mar; 29(6):609-17. PubMed ID: 6222508
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII.
    Greenberg CS; Achyuthan KE; Rajagopalan S; Pizzo SV
    Arch Biochem Biophys; 1988 Apr; 262(1):142-8. PubMed ID: 2895608
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Fibrinogenolysis and fibrinolysis with strenuous exercise.
    Ferguson EW; Barr CF; Bernier LL
    J Appl Physiol Respir Environ Exerc Physiol; 1979 Dec; 47(6):1157-61. PubMed ID: 536284
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Quantitative studies of the interaction between plasma and tissue components in human intima.
    Smith EB; Alexander KM; Massie IB
    Adv Exp Med Biol; 1977; 82():872-7. PubMed ID: 72489
    [No Abstract]   [Full Text] [Related]  

  • 69. [Studies on the fragments of FDP in 3 patients with DIC associated with acute promyelocytic leukemia].
    Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
    Rinsho Byori; 1993 Jun; 41(6):719-25. PubMed ID: 8361040
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Studies on the fragments of FDP in 4 patients with DIC].
    Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
    Rinsho Byori; 1992 Oct; 40(10):1089-95. PubMed ID: 1307614
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Plasmic degradation of bovine fibrinogen and non-crosslinked fibrins in solution and in gel form.
    Inoue N; Moroi M; Yamasaki M
    Biochim Biophys Acta; 1975 Aug; 400(2):322-33. PubMed ID: 240417
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Distinction between fibrinogen and fibrin degradation products in plasma.
    Gaffney PJ
    Clin Chim Acta; 1975 Nov; 65(1):109-15. PubMed ID: 1192601
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Protective effect of divalent cations in the plasmin degradation of fibrinogen.
    Dang CV; Bell WR; Ebert RF; Starksen NF
    Arch Biochem Biophys; 1985 May; 238(2):452-7. PubMed ID: 3158281
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Analysis of fibrinogen degradation product in severe liver disorders by immunoblotting.
    Tanaka M; Ohkita T
    Tohoku J Exp Med; 1987 Nov; 153(3):179-87. PubMed ID: 3433274
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Complex-formation between the fibrin-derived plasmic fragments DD and E demonstrated by crossed immunoelectrophoresis.
    Gogstad GO; Brosstad F
    Thromb Res; 1983 Jun; 30(5):441-8. PubMed ID: 6225217
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Injury and repair of smaller muscular and elastic arteries. Immunohistochemical demonstration of fibronectin and fibrinogen/fibrin and their degradation products in rabbit femoral and common carotid arteries following a dilatation injury.
    Rasmussen LH; Garbarsch C; Chemnitz J; Christensen BC; Lorenzen I
    Virchows Arch A Pathol Anat Histopathol; 1989; 415(6):579-85. PubMed ID: 2508316
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Conversion of fibrinogen to fibrin induced by preferential release of fibrinopeptide B.
    Dyr JE; Blombäck B; Hessel B; Kornalík F
    Biochim Biophys Acta; 1989 Jan; 990(1):18-24. PubMed ID: 2914147
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: in vivo evidence that lipoprotein(a) may contribute to foam cell formation.
    Nielsen LB; Juul K; Nordestgaard BG
    Arterioscler Thromb Vasc Biol; 1998 Apr; 18(4):641-9. PubMed ID: 9555871
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Interaction of fibrin(ogen) with fibronectin: further characterization and localization of the fibronectin-binding site.
    Makogonenko E; Tsurupa G; Ingham K; Medved L
    Biochemistry; 2002 Jun; 41(25):7907-13. PubMed ID: 12069579
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Fibrinogen and fibrinolysis in blood and in the arterial wall: its role in advanced atherosclerotic disease.
    Martin-Paredero V; Vadillo J; Diaz J; Espinosa A; Berga C; Segura J; Sanchez J; Barbod A; Villaverde C; Richard CM
    Cardiovasc Surg; 1998 Oct; 6(5):457-62. PubMed ID: 9794264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.